Ultrasound study to reveal hidden clues in Women's cancers
NCT ID NCT07385976
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study uses a special 3D ultrasound to look at blood flow inside cervical and ovarian tumors. Researchers want to see if blood flow patterns can help tell the difference between cancer and pre-cancer, and if they can predict how well patients will do over time. About 100 adult women with these conditions, plus a healthy control group, will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Women with cervical cancer, cervical intraepithelial neoplasm, ovarian cancer, and the disease-free control
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Regarding the topic "Hemoperfusion characteristics of cervical cancer and precancerous lesions, and the correlation between hemoperfusion and prognosis": 1. Adult women who have had a normal cervical smear within the past three years and have no other gynecological cancers (control group). 2. Adult women with cervical cancer or precancerous lesions. * Regarding the topic "Correlation between hemoperfusion and prognosis of ovarian cancer": 1. Adult women suspected of having ovarian cancer, fallopian tube cancer, or peritoneal cancer before surgery. Exclusion Criteria: * Regarding the topic "Hemoperfusion characteristics of cervical cancer and precancerous lesions of the cervix, and the correlation between hemoperfusion and prognosis": 1\. Patients who cannot cooperate with vaginal 3D ultrasound scans. * Regarding the topic "Correlation between hemoperfusion and prognosis of ovarian cancer": 1. Patients who cannot cooperate with vaginal or abdominal 3D ultrasound scans.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital,
New Taipei City, Banqiao, 22050, Taiwan
-
Far Eastern Memorial Hospital
New Taipei City, 220, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI and computer models predict how well cancer drugs reach tumors?
- Can a Patient's own immune cells fight ovarian cancer?
- Ovarian Cancer's spread: scientists probe abdominal fluid for clues
- New PET tracer aims to light up hidden cancer targets
- Can pulsed radiation extend life in metastatic cervical cancer?
- Can inhaled manganese make ovarian cancer immunotherapy hit harder?